Analyst Price Targets — STIM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 5, 2025 11:37 am | — | Canaccord Genuity | $8.00 | $5.42 | TheFly | Neuronetics price target raised to $8 from $5 at Canaccord |
| November 8, 2022 1:43 pm | Adam Maeder | Piper Sandler | $8.00 | $3.71 | TheFly | Neuronetics guidance appears conservative, says Piper Sandler |
Latest News for STIM
Neuronetics is revisited following prior coverage in March 2026. The article focuses on STIM's recent developments and their impact on the investment thesis. Key topics include operational progress, financial performance, and forward outlook for STIM.
MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that management will participate at the B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event…
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Robert Greene has been appointed as the company's Senior Vice President Sales, effective June 1,…
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced its participation as a Silver Sponsor at the 2026 Clinical TMS Society (CTMSS) Annual Meeting, where…
MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced a strategic partnership with ANT Neuro, a global leader in precision brain mapping and neuronavigation…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STIM.
U.S. House Trading
No House trades found for STIM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.